title: Renin inhibition: what are the therapeutic opportunities?
abstract: Blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers has become a crucial element in cardiovascular and renal medicine. This review evaluates the potential of renin inhibition as an adjunct to therapies that depend on renin system interruption.
authors.affiliation: Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
authors.forename: Naomi D L
authors.initials: ND
authors.lastname: Fisher
authors.forename: Norman K
authors.initials: NK
authors.lastname: Hollenberg
mesh_terms: D004151:Dipeptides / Q000627:therapeutic use*; D015195:Drug Design; D006801:Humans; D006977:Hypertension, Renal / Q000188:drug therapy*; D010455:Peptides / Q000737:chemistry / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D012084:Renin-Angiotensin System / Q000187:drug effects*; D013844:Thiazoles / Q000627:therapeutic use; D000092502:Renin Inhibitors
chemical_list: D004151:Dipeptides; D010455:Peptides; D010879:Piperazines; D013844:Thiazoles; D000092502:Renin Inhibitors; C056622:enalkiren; C076903:zankiren hydrochloride